绥美凯上市了吗？

Is it on the market? Suimeike was developed by ViiV Healthcare (a joint venture of GlaxoSmithKline and Pfizer) and was approved by the US FDA on August 27, 2014 for the treatment of human immunodeficiency virus (HIV).

On January 22, 2018, GlaxoSmithKline (GSK) announced that its new drug Suimeike (generic name: dolutegravir tablets) for the treatment of HIV was officially launched in mainland China. This is a single-pill compound preparation with the new generation integrase inhibitor dolutegravir (DTG) as the core. It is also the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. 

The launch of Suimeike in my country provides a new treatment option for domestic HIV patients. In clinical trials, Suimeike has a significantly higher virus-inhibiting effect, has fewer side effects, and rarely leads to discontinuation of treatment. Moreover, Suimeikai is an oral tablet, which is easy to use, reducing the patient's medication burden and improving the patient's compliance. The method of use of Suimeikai is to take one tablet orally once a day. If the patient weighs less than 40KG, it cannot be used because Suimeikai is a fixed dose and cannot be reduced.

Individual formulations of abacavir, dolutegravir, or lamivudine may be used if discontinuation or dose adjustment of one of the active ingredients is necessary and, in these circumstances, physicians should refer to the respective product information for these medicines. There are no clinical data in patients with moderate or severe hepatic impairment and therefore its use is not recommended unless considered necessary.

It has been approved for marketing in more than 50 countries or regions, including my country, and has been recommended by many authoritative institutions in Europe and the United States as a first-line drug for newly treated HIV-infected patients. More and more HIV patients have benefited from it. In addition to my country, Suimeikai, which is listed in India, is currently the lowest priced. Patients can also consult the medical companion travel service for specific information.